Sensei Biotherapeutics net loss deepens to $170.2M on Faeth acquisition charges
Sensei Biotherapeutics (NASDAQ:SNSE) reported a significantly wider net loss for the first quarter of 2026, primarily driven by massive, one-time accounting charges stemming from its transformational acquisition of Faeth Therapeutics Inc. earlier in the year.



_1400503_640x360_2500118595818-640x360.webp&w=3840&q=75)





_1400450_640x360_2500099651781-640x360.webp&w=3840&q=75)
_1400443_640x360_2500099139759-640x360.webp&w=3840&q=75)
_1400402_640x360_2500095043865-640x360.webp&w=3840&q=75)